Bio­gen pressed against the wall as more stake­hold­ers side against Aduhelm; Prime time for CRISPR 3.0?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As the End­points team grows, we are find­ing more time to do in­ter­views un­der em­bar­goes and pur­sue more in-depth fea­tures — per­son­al­ly two of my fa­vorite parts of this job. Got news lined up in the near fu­ture? You can al­ways reach us at ed­i­to­r­i­al@end­

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.